Report ID :10294014 |
Published Date : 21 Oct 2022 |
Report Format : |
Delivery Timeline :48-72 Business Hours
REPORT HIGHLIGHTS
The transplantation market was valued at USD 24.93 billion by 2017, growing with 8.8% CAGR during the forecast period, 2018-2025
Market Dynamics
Organ transplantation is an in-demand field of medical science. It encompasses replacing the non-functional organs of patients with a fully functional element from a matched donor. This procedure is most common for kidney, liver, heart, eyes among others. The U.S. Government Information on Organ Donation and Transplantation stated that as of January 2019, over 113,000+ number of patient’s transplant is in waiting list. The organization also mentioned that the tissue transplant is increasing at rapid pace with more than 1 million procedure performed every year. Thus the demand of the industry unquestionably on a rise.
While the demand-supply gap between donors and recipients is only rising, the pharmaceutical industry is working effectively on improving procedures that enhance success rates of these procedures. An article in CNBC, 2017 stated that medical experts are using newer tools to combat the problems related to organ transplant. For instance, development of tools like norothermic perfusion, allows the organ to be in a body like environment using scientific procedures, thus enhancing chances of success. New technologies such as tissue products, tissue typing technology and surgical medical instruments have further propelled the growth of this industry significantly. Tissue banks are commonly used to store the tissue that would be used for these procedures. The American Association of Tissue Banks suggested that more than 120 accredited tissue banks are associated with them. This increasing number is also considered to be the key cause of industry growth. However, shortage of organ donor in the market and the rejection rate when it comes to organ transplantation pull back the market growth to some extent.
Product Takeaway
Based on products, the market is categorized into immunosuppressive drugs, preservation solutions, and tissue products. Tissue transfer procedure is one of the highest revenue generating segment. Followed by which, immunosuppressive drugs show the most promising growth. A study published in the American Journal of Transplantation, 2016 mentioned that immunosuppressant drugs could be the future of transplantation industry as it reducing the rejection risk and eventually increase success rates of transplantation. It is noted that more and more pharmaceutical companies are spending their R&D money on improving the portfolio of this product category, supporting the segment growth. On contrary, preservation solution category is seen to be growing at a rapid pace due to its increased usage in transplantation procedures.
Application Takeaway
Application wise, the two major categories are; tissue and organ transplantation. Of these, tissue method accounted for the significant revenue share owing to the increasing number of corneal transplants across the globe. As per the American Transplant Foundation, more than 40,000 corneal transplant procedure take place every year in the U.S. alone. This is followed by organ transplantation, growing with 8.5% CAGR during the study period. Based on statistics published on the website of Finger Lakes Donor Recovery Network, one new person is added to the organ transplant list every 10 minutes.
End-Use Takeaway
End-user segment is divided into hospitals, transplant centres and others. Hospitals recorded USD 13.21 billion in 2017 and is projected to maintain its dominance over the study period. Hospital facilities are now getting more equipped to carry out complete organ preservation and transplantation processes. Thus, these facilities are considered to be the key place where most transplant-related decisions occur, driving the segment growth to great extent.
Regional Takeaway
North America is one of the leaders of this market due to the effective steps carried out by key players to improve transplant procedures. In addition, new rules and guidelines are being implemented by government that are constantly improving the scope of organ transplantation industry in region. Europe is accounted for the 30% revenue share owing to the increasing number of organ donor. Based on data published in 2017, MINISTERIO DE SANIDAD, Spain was the leader in terms of organ donation.
Key Vendor Takeaway
This industry is fragmented and includes various players include AbbVie Inc.; Zimmer Biomet; Medtronic; Teva Pharmaceuticals; Stryker; 21st Century Medicine; BioLife Solutions, Inc.; Novartis AG; Arthrex, Inc..; and Veloxis Pharmaceuticals. Novartis took over Selexys Pharmaceuticals in the year 2016, it has gone ahead to launch drug called Zortress which prevents organ rejection in adult liver transplantation patients.
The market size and forecast for each segment and sub-segments has been considered as below:
Historical Year – 2014 & 2016
Base Year – 2017
Estimated Year – 2018
Projected Year – 2025
TARGET AUDIENCE
Traders, Distributors, and Suppliers
Manufacturers
Government and Regional Agencies and Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
MARKET, BY PRODUCT
Immunosuppressive Drugs
Preservation Solutions
Tissue Products
MARKET, BY TYPE
Tissue Transplantation
Organ Transplantation
MARKET, BY END USE
Hospitals
Transplant Centers
Others
MARKET, BY REGION
North America
U.S.
Canada
Europe
Germany
France
Rest of Europe
Asia Pacific
India
China
Rest of APAC
Rest of the World
Middle East and Africa
Latin America
㱰
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
